Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Radiation therapy can promote amphiregulin, which increases growth of metastases

3.

For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.

4.

DNA origami offers more accurate imaging in the fight against pancreatic cancer

5.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot